SMMT — Summit Therapeutics Cashflow Statement
0.000.00%
- $5.48bn
- $5.42bn
- 55
- 18
- 84
- 51
Annual cashflow statement for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 January 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 9.9 | -52.7 | -88.6 | -78.8 | -615 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 9.03 | 2.42 | 14.7 | 27.3 | 540 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -54.9 | 0.619 | -0.067 | 8.62 | -2.37 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -35.1 | -48.1 | -72.6 | -41.6 | -76.8 |
Capital Expenditures | -0.164 | -0.421 | -0.306 | -0.624 | -0.128 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.167 | 0 | — | — | -588 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.331 | -0.421 | -0.306 | -0.624 | -588 |
Financing Cash Flow Items | -1.71 | -0.048 | -0.172 | -0.155 | -0.619 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 44.5 | 50.6 | 77.9 | 620 | 86.5 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 6.75 | 2.58 | 5.37 | 577 | -577 |